Literature DB >> 30159903

Mitochondrial diseases and status epilepticus.

Shamima Rahman1,2.   

Abstract

This narrative review focuses on the pathophysiology, diagnosis, and management of status epilepticus in the context of primary mitochondrial disease. Epilepsy is common in mitochondrial disease, reported in >20% of adult cases and 40%-60% of pediatric cohorts. Status epilepticus is less frequently reported and appears to be associated with particular subgroups of mitochondrial disorders, namely defects of the mitochondrial DNA and its maintenance, and disorders of mitochondrial translation and dynamics. Mechanisms underlying mitochondrial status epilepticus are incompletely understood, and may include bioenergetic failure, oxidative stress, immune dysfunction, and impaired mitochondrial dynamics. Treatments tried in mitochondrial status epilepticus include antiepileptic drugs, anesthetic agents, magnesium, high-dose steroids, immune globulins, vagus nerve stimulation, and surgical procedures, all with variable success. The outcome of mitochondrial status epilepticus is extremely poor, and effective therapeutic options have not been reported. Improved understanding of the mechanisms underpinning mitochondrial status epilepticus is needed in order to develop more effective treatments. Wiley Periodicals, Inc.
© 2018 International League Against Epilepsy.

Entities:  

Keywords:  zzm321990zzm321990POLGzzm321990zzm321990; mitochondrial dynamics; mitochondrial epilepsy pathophysiology; mitochondrial translation; treatment

Mesh:

Substances:

Year:  2018        PMID: 30159903     DOI: 10.1111/epi.14485

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

Review 1.  Progress on mitochondrial silence information regulator family in epilepsy.

Authors:  Feng Zhu; Yingchun Xiang; Linghui Zeng
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

2.  Effective application of corpus callosotomy in pediatric intractable epilepsy patients with mitochondrial dysfunction.

Authors:  Ji-Hoon Na; Heung Dong Kim; Young-Mock Lee
Journal:  Ther Adv Neurol Disord       Date:  2022-04-21       Impact factor: 6.430

Review 3.  Mitochondrial disorders and drugs: what every physician should know.

Authors:  Daniele Orsucci; Elena Caldarazzo Ienco; Gabriele Siciliano; Michelangelo Mancuso
Journal:  Drugs Context       Date:  2019-07-04

4.  Clinical Characteristics of Early-Onset and Late-Onset Leigh Syndrome.

Authors:  Chan-Mi Hong; Ji-Hoon Na; Soyoung Park; Young-Mock Lee
Journal:  Front Neurol       Date:  2020-04-15       Impact factor: 4.003

5.  Delay in diagnosing a patient with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome who presented with status epilepticus and lactic acidosis: a case report.

Authors:  Ahmad F Alenezi; Mariam A Almelahi; Feten Fekih-Romdhana; Haitham A Jahrami
Journal:  J Med Case Rep       Date:  2022-10-10

6.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

Review 7.  Epilepsy in Mitochondrial Diseases-Current State of Knowledge on Aetiology and Treatment.

Authors:  Dorota Wesół-Kucharska; Dariusz Rokicki; Aleksandra Jezela-Stanek
Journal:  Children (Basel)       Date:  2021-06-22

8.  The Protective Role of E-64d in Hippocampal Excitotoxic Neuronal Injury Induced by Glutamate in HT22 Hippocampal Neuronal Cells.

Authors:  RuiJin Xie; TianXiao Li; XinYu Qiao; HuiYa Mei; GuoQin Hu; LongFei Li; Chenyu Sun; Ce Cheng; Yin Cui; Ni Hong; Yueying Liu
Journal:  Neural Plast       Date:  2021-10-20       Impact factor: 3.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.